NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

News and Updates

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

Seventy new COST Actions approved

Published on | 1 year ago

Programmes COST  

The COST Commitee of Senior Officials (CSO) has recently approved 70 new COST Actions (results from OC-2022-1) that will have their first kick-off meetings between September and November 2023. An overview of the newly approved COST Actions can be found here.

Since 2021, all COST Member States (including Belgium) are part of new COST Actions once approved by the CSO. Researchers and innovators in Belgium can directly participate in these new COST Actions. Applications for participation to the working groups of the COST Actions can be submitted through the e-cost platform and are subjected to the approval of the management committee of the COST Action. Working groups perform the tasks required by the COST Action to fulfil the objectives of the network’s project plan.

When submitting an application for participation to the working groups you can also indicate your wish to be part of the management committee. The management committee supervises and coordinates the proper implementation and management of the respective COST Action. Applications for participation to the management committee are however subjected to an additional national application procedure. Please contact FWO for further guidance regarding the application procedure for participation in the management committee. Each COST Member State can nominate up to two national representatives in the management committee of a COST Action. On page 5 of the rules for COST Actions (level B) document you will find more information about the role and responsibilities of the management committee members.

Please note that it is strongly encouraged and advised to contact the main proposer or Chair of the COST Action in advance if you would like to join the COST Action to discuss your participation and contribution to the COST Action. All contact details of Action representatives can be found on the COST Website. More details for the 70 newly approved COST Actions will be available on the COST Website as from 9 June 2023. Any further queries related to COST can be directed to cost@fwo.be or more information on how to participate in COST can also be found here.

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1504 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.